ADC Therapeutics SA (ADCT)
1.22
-0.08
(-6.15%)
USD |
NYSE |
Sep 09, 16:00
1.22
0.00 (0.00%)
After-Hours: 16:48
ADC Therapeutics EPS Diluted (Quarterly) : -0.1069 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1069 |
| March 31, 2026 | -0.2139 |
| December 31, 2025 | -0.0426 |
| September 30, 2025 | -0.3002 |
| June 30, 2025 | -0.498 |
| March 31, 2025 | -0.3601 |
| December 31, 2024 | -0.2915 |
| September 30, 2024 | -0.4195 |
| June 30, 2024 | -0.3819 |
| March 31, 2024 | -0.5646 |
| December 31, 2023 | -1.033 |
| September 30, 2023 | -0.568 |
| June 30, 2023 | -0.6005 |
| March 31, 2023 | -0.7348 |
| December 31, 2022 | -0.2901 |
| September 30, 2022 | -0.6457 |
| June 30, 2022 | -0.837 |
| March 31, 2022 | -0.2169 |
| December 31, 2021 | -0.4477 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.9324 |
| June 30, 2021 | -0.9458 |
| March 31, 2021 | -0.6716 |
| December 31, 2020 | -0.729 |
| September 30, 2020 | -0.2867 |
| June 30, 2020 | -2.013 |
| March 31, 2020 | -0.6501 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 2.050 |
| AC Immune SA | 0.026 |
| CRISPR Therapeutics AG | -0.9445 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -16.56M |
| Revenue (Quarterly) | 19.25M |
| Total Expenses (Quarterly) | 35.81M |
| Enterprise Value | 64.13M |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -86.06% |
| Earnings Yield | -54.39% |
| Normalized Earnings Yield | -67.81 |